Resource Summary Report

Generated by NIF on Sep 1, 2026

EGF Receptor (L858R Mutant Specific) (43B2) Rabbit mAb

RRID:AB_1903955
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3197, RRID:AB_1903955

Antibody Information

URL: http://antibodyregistry.org/AB_1903955

Proper Citation: Cell Signaling Technology Cat# 3197, RRID:AB_1903955

Target Antigen: EGFR (L858R Mutant Specific) (43B2) Rabbit mAb detects endogenous levels of EGFR mutant L858R protein. Careful titration of this antibody may be required to obtain optimal specificity.

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-P, IF-IC, F
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: EGF Receptor (L858R Mutant Specific) (43B2) Rabbit mAb

Description: This monoclonal targets EGFR (L858R Mutant Specific) (43B2) Rabbit mAb detects endogenous levels of EGFR mutant L858R protein. Careful titration of this antibody may be required to obtain optimal specificity.

Target Organism: human

Clone ID: [43B2]

Antibody ID: AB_1903955

Vendor: Cell Signaling Technology

Catalog Number: 3197

Record Creation Time: 20250819T212412+0000

Record Last Update: 20250819T225022+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for EGF Receptor (L858R Mutant Specific) (43B2) Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Pandya T, et al. (2026) Plasma signals of lung tumor promotion for molecular cancer prevention. Cell, 189(13), 3903.

Kuhlmann-Hogan A, et al. (2023) EGFR + lung adenocarcinomas coopt alveolar macrophage metabolism and function to support EGFR signaling and growth. bioRxiv : the preprint server for biology.

Lin YC, et al. (2023) CAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer. iScience, 26(3), 106089.

Tanaka K, et al. (2021) Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer cell, 39(9), 1245.